Evidence that bone morphogenetic protein 4 has multiple biological functions during kidney and urinary tract development. *Yoichi Miyazaki, Keisuke Oshima, Agnes Fogo, and Iekuni Ichikawa* 835

Polymorphisms in the nephrin gene and diabetic nephropathy in type 1 diabetic patients. *Kim Pettersson-Fernholm, Carol Forsblom, Markus Perola, and Per-Henrik Groop, for the FinnDiane Study Group* ... 1205

Association of an *IL-1A* 3′UTR polymorphism with end-stage renal disease and IL-1α expression. *Jeannette T. Bensen, Carl D. Langefeld, Liwu Li, Charles E. McCall, Susan L. Cousart, Bonnie N. Dryman, Barry I. Freedman, and Donald W. Bowden* 1211

Delayed cystogenesis and increased ciliogenesis associated with the re-expression of polaris in *Tg737* mutant mice. *Nicole E. Brown and Noel S. Murcia* 1220

Evidence that soyasaponin B_b retards disease progression in a murine model of polycystic kidney disease. *Diana J. Philbrick, Dominique P. Bureau, F. William Collins, and Bruce J. Holub* 1230

Cux-1 transgenic mice develop glomerulosclerosis and interstitial fibrosis. *Jennifer G. Brantley, Madhulika Sharma, Neal I. Akcalay, and Gregory B. Vanden Heuvel* 1240

The Rho family of small GTPases is involved in epithelial cystogenesis and tubulogenesis. *Katherine K. Rogers, Tzuu-Shuh Jou, Wei Guo, and Joshua H. Lipschutz* 1632

Atypical familial juvenile hyperuricemic nephropathy associated with a hepatocyte nuclear factor-1β gene mutation. *Coralie Bingham, Sian Ellard, William G. van't Hoff, H. Anne Simmonds, Anthony M. Marinaki, Michael K. Badman, Peter H. Winocour, Amanda Stride, Christopher R. Lockwood, Anthony J. Nicholls, Katharine R. Owen, Ghislaine Spyer, Ewan R. Pearson, and Andrew T. Hattersley* 1645

A novel lysozyme mutation Phe57Ile associated with hereditary renal amyloidosis. *Masahide Yazaki, Sandra A. Farrell, and Merrill D. Benson* 1652

Imprinted mesodermal specific transcript (*MEST*) and *H19* genes in renal development and diabetes. *Yashpal S. Kanwar, Xiaomin Pan, Sun Lin, Anil Kumar, Jun Wada, Christian S. Haas, Gene Liau, and Jon W. Lomasney* 1658

Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. *Tamio Yamaguchi, Shizuko Nagao, Darren P. Wallace, Franck A. Belibi, Benjamin D. Cowley, Jr., Jill C. Pelling, and Jared J. Grantham* 1983

Mutation analysis and clinical implications of von Willebrand factor–cleaving protease deficiency. *Karin Assink, Rikke Schiphorst, Sarah Allford, Diana Karpman, Amos Etzioni, Bénédicte Brichard, Nicole van de Kar, Leo Monnens, and Lambertus van den Heuvel* 1995

HORMONES – CYTOKINES – SIGNALING

Growth factor-mediated phosphorylation of proapoptotic BAD reduces tubule cell death in vitro and in vivo. *Susan C. Kiley, Barbara A. Thornhill, Shiow-Shih Tang, Julie R. Ingelfinger, and Robert L. Chevalier* 33

Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. *Iris Feria, Israel Pichardo, Patricia Juárez, Victoria Ramírez, Marco A. González, Norma Uribe, Romeo García-Torres, Fernando López-Casillas, Gerardo Gamba, and Norma A. Bobadilla* 43

Expression of somatostatin receptors 3, 4, and 5 in mouse kidney proximal tubules. *Carlton M. Bates, Heather Kegg, Christina Petrevski, and Sandy Grady* 53

Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats. *Can Li, Chul Woo Yang, Cheol Whee Park, Hee Jong Ahn, Wan Young Kim, Kun Ho Yoon, Sun Hee Suh, Sun Woo Lim, Jung Ho Cha, Yong Soo Kim, Jin Kim, Yoon Sik Chang, and Byung Kee Bang* 454

Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells. *Sho-ichi Yamagishi, Yosuke Inagaki, Tamami Okamoto, Shinjiro Amano, Kohachiro Koga, and Masayoshi Takeuchi* 464

Contents continued on next page

Tumor necrosis factor-α stimulates fractalkine production by mesangial cells and regulates monocyte transmigration: Down-regulation by cAMP. *Yung-Ming Chen, Shuei-Liong Lin, Ching-Wen Chen, Wen-Chih Chiang, Tun-Jun Tsai, and Bor-Shen Hsieh* 474

PTH ameliorates acidosis-induced adverse effects in skeletal growth centers: The PTH–IGF-I axis. *Jacob Green, Ruth Goldberg, and Gila Maor* 487

Gene transfer of truncated IκBα prevents tubulointerstitial injury. *Osamu Takase, Junichi Hirahashi, Atsushi Takayanagi, Akihiro Chikaraishi, Takeshi Marumo, Yuri Ozawa, Matsuhiko Hayashi, Nobuyoshi Shimizu, and Takao Saruta* 501

Increased endothelin-1 expression in the kidney in hypercalcemic rats. *Naoki Shiraishi, Kenichiro Kitamura, Yukimasa Kohda, Takefumi Narikiyo, Masataka Adachi, Taku Miyoshi, Kozo Iwashita, Hiroshi Nonoguchi, R. Tyler Miller, and Kimio Tomita* 845

GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. *Prabal K. Chatterjee, Nimesh S.A. Patel, Ahila Sivarajah, Espen O. Kvale, Laura Dugo, Salvatore Cuzzocrea, Paul A.J. Brown, Keith N. Stewart, Helder Mota-Filipe, Domenico Britti, Muhammad M. Yaqoob, and Christoph Thiemermann* 853

Calpain is activated in experimental uremia: Is calpain a mediator of uremia-induced myocardial injury? *Steven M. Harwood, David A. Allen, Alistair M.S. Chesser, David I. New, Martin J. Raftery, and Muhammad M. Yaqoob* 866

Glucose-induced fibronectin and collagen type III expression in renal fibroblasts can occur independent of TGF-β1. *Suzanne Lam, Nicole A.M. Verhagen, Frank Strutz, Johan W. van der Pijl, Mohamed R. Daha, and Cees van Kooten* 878

Monocyte adhesion to mesangial matrix modulates cytokine and metalloproteinase production. *Ravinder S. Chana, John Martin, Enam U. Rahman, and David C. Wheeler* 889

IL-1β, TNF-α, TGF-β, and *b*FGF expression in bone biopsies before and after parathyroidectomy. *Francisco R. Lello Santos, Rosa M.A. Moysés, Fábio L.M. Montenegro, Vanda Jorgetti, and Irene L. Noronha* 899

IGF-I induces vascular endothelial growth factor in human mesangial cells via a Src-dependent mechanism. *Gabriella Gruden, Shawanna Araf, Silvia Zonca, Davina Burt, Stephen Thomas, Luigi Gnudi, and Gian Carlo Viberti* (see Editorial by Cooper and Thomas, p. 1584) 1249

Activation of the ERK pathway precedes tubular proliferation in the obstructed rat kidney. *Takao Masaki, Rita Foti, Prudence A. Hill, Yohei Ikezumi, Robert C. Atkins, and David J. Nikolic-Paterson* 1256

Induction of MIF synthesis and secretion by tubular epithelial cells: A novel action of angiotensin II. *Edwina K. Rice, Gregory H. Tesch, Zemin Cao, Mark E. Cooper, Christine N. Metz, Richard Bucala, Robert C. Atkins, and David J. Nikolic-Paterson* 1265

ET_A receptor-mediated Ca^{2+} signaling in thin descending limbs of Henle's loop: Impairment in genetic hypertension. *Matthew A. Bailey, Celine Haton, Valerie Orea, Jean Sassard, Claire Bailly, Robert J. Unwin, and Martine Imbert-Teboul* 1276

Role of Smad4 on TGF-β–induced extracellular matrix stimulation in mesangial cells. *Ken-ichi Tsuchida, Yanqing Zhu, Senthuran Siva, Stephen R. Dunn, and Kumar Sharma* 2000

Role of TGF-β signaling in extracellular matrix production under high glucose conditions. *Jin H. Li, Xiao R. Huang, Hong-Jian Zhu, Richard Johnson, and Hui Y. Lan* 2010

Efficacy of 19-Nor-1,25-$(OH)_2D_2$ in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. *Eduardo Slatopolsky, Mario Cozzolino, Yan Lu, Jane Finch, Andriana Dusso, Marc Staniforth, Yoo Wein, and Jee Webster* 2020

Transforming growth factor-β1 increases glucocorticoid binding and signaling in macrophages through a Smad- and activated protein-1–mediated process. *Julie Peltier, Joëlle Perez, Agnès Bellocq, Brigitte Escoubet, Bruno Fouqueray, and Laurent Baud* (see Editorial by Steinmetz and Stahl, p. 2317) 2028

Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. *Song Wang, Qing Chen, Theodore C. Simon, Frank Strebeck, Lala Chaudhary, Jeremiah Morrissey, Helen Liapis, Saulo Klahr, and Keith A. Hruska* 2037

CELL BIOLOGY – IMMUNOLOGY – PATHOLOGY

Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. *Gozewijn D. Laverman, Harry van Goor, Robert H. Henning, Paul E. de Jong, Dick de Zeeuw, and Gerjan Navis* 64

Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. *Kazuhiko Tsuruya, Toshiharu Ninomiya, Masanori Tokumoto, Makoto Hirakawa, Kohsuke Masutani, Masatomo Taniguchi, Kyoichi Fukuda, Hidetoshi Kanai, Kenji Kishihara, Hideki Hirakata, and Mitsuo Iida* 72

Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. *Yohei Ikezumi, Lynette A. Hurst, Takao Masaki, Robert C. Atkins, and David J. Nikolic-Paterson* 83

Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. *Mira Choi, Susanne Rolle, Madhavi Rane, Hermann Haller, Friedrich C. Luft, and Ralph Kettritz* 96

Hypercholesterolemia is a prerequisite for puromycin inducible damage in mouse kidney. *Zhu-Zhu Cheng, Anu Pätäri, Katriina Aalto-Setälä, Dmitry Novikov, Detlef Schlöndorff, and Harry Holthöfer* 107

Mitotic cell cycle proteins increase in podocytes despite lack of proliferation. *Arndt T. Petermann, Jeffrey Pippin, Keiju Hiromura, Toshi Monkawa, Raghu Durvasula, William G. Couser, Jeffrey Kopp, and Stuart J. Shankland* 113

Sepsis syndrome stimulates proximal tubule cholesterol synthesis and suppresses the SR-B1 cholesterol transporter. *Richard A. Zager, Ali C.M. Johnson, and Sherry Y. Hanson* 123

A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. *Thiruma V. Arumugam, Ian A. Shiels, Anna J. Strachan, Giovani Abbenante, David P. Fairlie, and Stephen M. Taylor* 134

Complexes of IgA with FcαRI/CD89 are not specific for primary IgA nephropathy. *Paul J.M. van der Boog, Johan W. de Fijter, Cees van Kooten, Rutger van der Holst, Anneke van Seggelen, Leendert A. van Es, and Mohamed R. Daha* 514

Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. *Fuad S. Shihab, William M. Bennett, Jorge Isaac, Hong Yi, and Takeshi F. Andoh* 522

Induction of DNA synthesis by ligation of the CD53 tetraspanin antigen in primary cultures of mesangial cells. *Mónica Yunta, Alicia Rodríguez-Barbero, Miguel A. Arévalo, José M. López-Novoa, and Pedro A. Lazo* 534

Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. *Veerle P. Persy, Anja Verhulst, Dirk K. Ysebaert, Kathleen E. De Greef, and Marc E. De Broe* 543

Bioflavonoids attenuate renal proximal tubular cell injury during cold preservation in Euro-Collins and University of Wisconsin solutions. *Thurid Ahlenstiel, Gunther Burkhardt, Hans Köhler, and Martin K. Kuhlmann* 554

Ureteral obstruction in neonatal mice elicits segment-specific tubular cell responses leading to nephron loss. *François Cachat, Bärbel Lange-Sperandio, Alice Y. Chang, Susan C. Kiley, Barbara A. Thornhill, Michael S. Forbes, and Robert L. Chevalier* (see Editorial by Woolf, p. 761) 564

Growth factor expression in a murine model of cryoglobulinemia. *Sekiko Taneda, Kelly L. Hudkins, Yan Cui, Andrew G. Farr, Charles E. Alpers, and Stephan Segerer* 576

A novel mechanism of nephron loss in a murine model of crescentic glomerulonephritis. *Michel Le Hir and Valérie Besse-Eschmann* 591

Contents continued on next page

Modulation of renal epithelial barrier function by mitogen-activated protein kinases (MAPKs): Mechanism of cyclosporine A–induced increase in transepithelial resistance. *Breda Kiely, Gemma Feldman, and Michael P. Ryan* 908

Rapamycin is an effective inhibitor of human renal cancer metastasis. *Fu L. Luan, Ruchuang Ding, Vijay K. Sharma, W. James Chon, Milagros Lagman, and Manikkam Suthanthiran* 917

Dose-dependent effects of strontium on bone of chronic renal failure rats. *Iris Schrooten, Geert J.S. Behets, Walter E. Cabrera, Sven R. Vercauteren, Ludwig V. Lamberts, Steven C. Verberckmoes, An J. Bervoets, Geert Dams, William G. Goodman, Marc E. De Broe, and Patrick C. D'Haese* 927

Shedding of growth-suppressive gangliosides from glomerular mesangial cells undergoing apoptosis. *Nobuo Tsuboi, Yasunori Utsunomiya, Tetsuya Kawamura, Tetsuro Kikuchi, Tatsuo Hosoya, Tsuneya Ohno, and Hisashi Yamada* 936

Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. *Bing-Fen Liu, Satoshi Miyata, Yushi Hirota, Satomi Higo, Hiroyuki Miyazaki, Michiru Fukunaga, Yasuhiro Hamada, Shigemitsu Ueyama, Osamu Muramoto, Atsuko Uriuhara, and Masato Kasuga* 947

High glucose activates the p38 MAPK pathway in cultured human peritoneal mesothelial cells. *Zhong-Gao Xu, Kyung Sik Kim, Hyeong Cheon Park, Kyu Hun Choi, Ho Yung Lee, Dae Suk Han, and Shin-Wook Kang* 958

Altered polarity and expression of H^+-ATPase without ultrastructural changes in kidneys of Dent's disease patients. *Pierre Moulin, Takashi Igarashi, Patrick Van Der Smissen, Jean-Pierre Cosyns, Pierre Verroust, Rajesh V. Thakker, Steven J. Scheinman, Pierre J. Courtoy, and Olivier Devuyst* 1285

Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. *Kerstin Amann, Johannes Törnig, Birgit Kugel, Marie-Luise Gross, Karin Tyralla, Abdussalam El-Shakmak, András Szabo, and Eberhard Ritz* 1296

Specific inhibition of *Egr-1* prevents mesangial cell hypercellularity in experimental nephritis. *Marina Carl, Yoshitaka Akagi, Sven Weidner, Yoshitaka Isaka, Enyu Imai, and Harald D. Rupprecht* 1302

Crystal attachment to injured renal collecting duct cells: Influence of urine proteins and pH. *John H. Wiessner, Linda Y. Hung, and Neil S. Mandel* 1313

Distinct distribution of specific members of protein 4.1 gene family in the mouse nephron. *Mohamed Ramez, Marcel Blot-Chabaud, Françoise Cluzeaud, Sumita Chanan, Michael Patterson, Loren D. Walensky, Shirin Marfatia, Anthony J. Baines, Joel A. Chasis, John G. Conboy, Narla Mohandas, and Philippe Gascard* 1321

Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis. *Kathryn D. Rodgers, Velidi Rao, Daniel T. Meehan, Nicole Fager, Philip Gotwals, Sarah T. Ryan, Victor Koteliansky, Ryoichi Nemori, and Dominic Cosgrove* (see Editorial by Nikolic-Paterson, p. 1582) 1338

Melatonin induced cyclic modulation of vectorial water transport in kidney-derived MDCK cells. *Gerardo Ramírez-Rodríguez, Isaura Meza, María Eugenia Hernández, Aída Castillo, and Gloria Benítez-King* .. 1356

Intussusceptive capillary growth is required for glomerular repair in rat Thy-1.1 nephritis. *Mitsuru Notoya, Toshihiro Shinosaki, Tatsuo Kobayashi, Tatsuo Sakai, and Hidetake Kurihara* 1365

Cell-cycle regulatory proteins in podocyte cell in idiopathic nephrotic syndrome of childhood. *Tarak Srivastava, Robert E. Garola, Joan M. Whiting, and Uri S. Alon* 1374

L-Arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. *Harm Peters, Wayne A. Border, Matthias Rückert, Stephanie Krämer, Hans-H. Neumayer, and Nancy A. Noble* 1382

Preconditioning with tin-protoporphyrin IX attenuates ischemia/reperfusion injury in the rat kidney. *Takashi Kaizu, Tohru Tamaki, Mitsuko Tanaka, Yasushi Uchida, Sei-Ichiro Tsuchihashi, Akio Kawamura, and Akira Kakita* 1393

Glucose-mediated induction of TGF-β1 and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent. *Teresa Y.H. Wong, Aled O. Phillips, Janusz Witowski, and Nicholas Topley* 1404

Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-κB and free radical in proximal tubular cells. *Masaru Motojima, Atsuko Hosokawa, Hideyuki Yamato, Takamura Muraki, and Toshimasa Yoshioka* 1671

Production of hemopexin by TNF-α stimulated human mesangial cells. *Jola J. Kapojos, Anke van den Berg, Harry van Goor, Maroeska W.M. te Loo, Klaas Poelstra, Theo Borghuis, and Winston W. Bakker* 1681

Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. *Hua Liu and Radhakrishna Baliga* 1687

ICAM-1 expression and leukocyte accumulation in inner stripe of outer medulla in early phase of ischemic compared to $HgCl_2$-induced ARF. *Kathleen E. De Greef, Dirk K. Ysebaert, Veerle Persy, Sven R. Vercauteren, and Marc E. De Broe* 1697

Cardiomyocyte loss in experimental renal failure: Prevention by ramipril. *Kerstin Amann, Karin Tyralla, Marie-Luise Gross, Ute Schwarz, Johannes Törnig, Christian Stefan Haas, Eberhard Ritz, and Gerhard Mall* 1708

Differential gene expression following early renal ischemia/reperfusion. *Suroj Supavekin, Weijia Zhang, Raju Kucherlapati, Frederick J. Kaskel, Leon C. Moore, and Prasad Devarajan* 1714

Inhibition of mitochondria prevents cell death in kidney epithelial cells by intra- and extracellular acidification. *Gerald Schwerdt, Ruth Freudinger, Claudia Schuster, Stefan Silbernagl, and Michael Gekle* 1725

Increased expression of MMP-2, MMP-9 (type IV collagenases/gelatinases), and MT1-MMP in canine X-linked Alport syndrome (XLAS). *Velidi H. Rao, George E. Lees, Clifford E. Kashtan, Ryochi Nemori, Rakesh K. Singh, Daniel T. Meehan, Kathyrn Rodgers, Brian R. Berridge, Gautam Bhattacharya, and Dominic Cosgrove* 1736

Effects of caspase inhibition on the progression of experimental glomerulonephritis. *Bin Yang, Timothy S. Johnson, John L. Haylor, Bart Wagner, Phil F. Watson, Mohsen M.H. El Kossi, Peter N. Furness, and A. Meguid El Nahas* 2050

Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-α–activated human peritoneal mesothelial cells. *Bettina Haslinger, Robert Kleemann, Karin H. Toet, and Teake Kooistra* 2065

Conditionally immortalized cell line of inducible metanephric mesenchyme. *Zoia B. Levashova, Sergei Y. Plisov, and Alan O. Perantoni* 2075

Microvascular and tubulointerstitial injury associated with chronic hypoxia-induced hypertension. *Marilda Mazzali, J. Ashley Jefferson, Zehmin Ni, Nosratola D. Vaziri, and Richard J. Johnson* 2088

Epigenetic and genetic analysis of p16 in dermal fibroblasts from type 1 diabetic patients with nephropathy. *Lixia Zeng, Yashpal S. Kanwar, Nail Amro, Carrie Phillips, Mark Molitch, Daniel Batlle, and Farhad R. Danesh* 2094

Correction of anemia in uremic mice by genetically modified peritoneal mesothelial cells. *Tom Einbinder, Yuval Sufaro, Igor Yusim, Gerardo Byk, Jutta Passlick-Deetjen, Cidio Chaimovitz, and Amos Douvdevani* 2103

Glomerular number and size in autopsy kidneys: The relationship to birth weight. *Michael Hughson, Alton B. Farris III, Rebecca Douglas-Denton, Wendy E. Hoy, and John F. Bertram* 2113

The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. *Nathan L. Alderson, Mark E. Chachich, Nancy N. Youssef, Robert J. Beattie, Maurice Nachtigal, Suzanne R. Thorpe, and John W. Baynes* 2123

Cell senescence in rat kidneys in vivo increases with growth and age despite lack of telomere shortening. *Anette Melk, Wipawee Kittikowit, Irwindeep Sandhu, Kieran M. Halloran, Paul Grimm, Bernhard M.W. Schmidt, and Philip F. Halloran* 2134

Contents continued on next page

Shortening of telomeres: Evidence for replicative senescence of T cells derived from patients with Wegener's granulomatosis. *Saskia Vogt, Christof Iking-Konert, Friederike Hug, Konrad Andrassy, and G. Maria Hänsch* 2144

ION CHANNELS – MEMBRANE TRANSPORT – INTEGRATIVE PHYSIOLOGY

Urate transport via human PAH transporter hOAT1 and its gene structure. *Kimiyoshi Ichida, Makoto Hosoyamada, Hiroaki Kimura, Michio Takeda, Yasunori Utsunomiya, Tatsuo Hosoya, and Hitoshi Endou* 143

Potential importance of glomerular citrate synthase activity in remnant nephropathy. *Michael E. Ullian, Benjamin J. Gantt, Amy K. Ford, Baby G. Tholanikunnel, Eleanor K. Spicer, and Wayne R. Fitzgibbon* 156

Reverse pharmacological effect of loop diuretics and altered rBSC1 expression in rats with lithium nephropathy. *Mari Michimata, Sayuri Fujita, Tsutomu Araki, Kazuhiko Mizukami, Itsuro Kazama, Yasuko Muramatsu, Michiko Suzuki, Tokihisa Kimura, Sei Sasaki, Yutaka Imai, and Mitsunobu Matsubara* 165

Acute renal failure leads to dysregulation of lung salt and water channels. *Hamid Rabb, Zhaohui Wang, Takashi Nemoto, John Hotchkiss, Naoko Yokota, and Manoocher Soleimani* 600

Expression of the K^+ channel Kir7.1 in the developing rat kidney: Role in K^+ excretion. *Yoshiro Suzuki, Yukiko Yasuoka, Takao Shimohama, Mariko Nishikitani, Nobuhiro Nakamura, Shigehisa Hirose, and Katsumasa Kawahara* 969

Sulfate conjugating and transport functions of MDCK distal tubular cells. *Kian Hong Ng, Beng Gek Lim, and Kim Ping Wong* 976

Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load. *Robert S. Pedersen, H. Bentzen, J.N. Bech, O. Nyvad, and E.B. Pedersen* 1417

Modeling study of human renal chloride channel (hCLC-5) mutations suggests a structural-functional relationship. *Fiona Wu, Philippe Roche, Paul T. Christie, Nellie Y. Loh, Anita A.C. Reed, Robert M. Esnouf, and Rajesh V. Thakker* 1426

Characterization of the endothelium-derived hyperpolarizing factor (EDHF) response in the human interlobar artery. *Eckhart Büssemaker, Rüdiger Popp, Jochen Binder, Rudi Busse, and Ingrid Fleming* 1749

Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. *Nosratola D. Vaziri, Tadashi Sato, and Kaihui Liang* 1756

Involvement of voltage- and ligand-gated Ca^{2+} channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. *Rudi D'Hooge, Gerda Van de Vijver, Pierre-Paul Van Bogaert, Bart Marescau, Raymond Vanholder, and Peter P. De Deyn* 1764

Reduced tubular cation transport in diabetes: Prevented by ACE inhibition. *Merlin C. Thomas, Chris Tikellis, Wendy C. Burns, Vicki Thallas, Josephine M. Forbes, Zemin Cao, Tanya M. Osicka, Leileata M. Russo, George Jerums, Hany Ghabrial, Mark E. Cooper, and Phillip Kantharidis* 2152

VASCULAR BIOLOGY – HEMODYNAMICS – HYPERTENSION

Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. *Norman K. Hollenberg, Deborah A. Price, Naomi D.L. Fisher, M. Cecilia Lansang, Bruce Perkins, Michael S. Gordon, Gordon H. Williams, and Lori M.B. Laffel* 172

Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. *Nosratola D. Vaziri, Michael Dicus, Nathan D. Ho, Laleh Boroujerdi-Rad, and Ram K. Sindhu* 179

Superoxide dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced hypertension. *Nosratola D. Vaziri, Ching-Yi Lin, Farbod Farmand, and Ram K. Sindhu* 186

Effects of diabetes, insulin and antioxidants on NO synthase abundance and NO interaction with reactive oxygen species. *Ja-Ryong Koo and Nosratola D. Vaziri* 195

Renal oxygenation defects in the spontaneously hypertensive rat: Role of AT_1 receptors. *William J. Welch, Horst Baumgärtl, Dietrich Lübbers, and Christopher S. Wilcox* 202

Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. *Ricardo Utimura, Clarice Kazue Fujihara, Ana Lúcia Mattar, Denise Maria Avancini Costa Malheiros, Irene de Lourdes Noronha, and Roberto Zatz* (see Editorial by Meyer, p. 377) 209

Low protein diet mediated renoprotection in remnant kidneys: Renal autoregulatory versus hypertrophic mechanisms. *Karen A. Griffin, Maria Picken, Anita Giobbie-Hurder, and Anil K. Bidani* 607

Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress. *Helga Frank, Hans-Paul Schobel, Jan Vitkowsky, Roland E. Schmieder, and Karsten Heusser* 617

Endothelial dysfunction and inflammation in asymptomatic proteinuria. *Karen E. Paisley, Martin Beaman, John E. Tooke, Vidya Mohamed-Ali, Gordon D.O. Lowe, and Angela C. Shore* 624

N-acetylcysteine ameliorates renal microcirculation: Studies in rats. *Samuel N. Heyman, Marina Goldfarb, Ahuva Shina, Fanny Karmeli, and Seymor Rosen* 634

The myogenic response in uremic hypertension. *David I. New, Alistair M.S. Chesser, Martin J. Raftery, and Magdi M. Yaqoob* 642

Glomerular autacoids stimulated by bradykinin regulate efferent arteriole tone. *YiLin Ren, Jeffrey L. Garvin, John R. Falck, Kishore V. Renduchintala, and Oscar A. Carretero* 987

Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension. *Edilia Tapia, Martha Franco, Laura G. Sánchez-Lozada, Virgilia Soto, Carmen Avila-Casado, José Santamaría, Yasmir Quiroz, Bernardo Rodríguez-Iturbe, and Jaime Herrera-Acosta* 994

Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. *Sharon M. Moe, Danxia Duan, Brian P. Doehle, Kalisha D. O'Neill, and Neal X. Chen* 1003

Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cells. *Zhi-Zhang Yang and Ai-Ping Zou* 1012

Sexual dimorphism in the aging kidney: Effects on injury and nitric oxide system. *Aaron Erdely, Ziv Greenfeld, Laszlo Wagner, and Chris Baylis* 1021

Morphometric study of arterioles and glomeruli in the aging kidney suggests focal loss of autoregulation. *Gary S. Hill, Didier Heudes, and Jean Bariéty* (see Editorial by Olson, p. 1162) 1027

Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure. *Jenny M. Cross, Ann E. Donald, Sarah L. Nuttall, John E. Deanfield, Robin G. Woolfson, and Raymond J. MacAllister* 1433

Interactions between gender and the angiotensin type 1 receptor gene polymorphism. *Heather Reich, John A. Duncan, Jordan Weinstein, Daniel C. Cattran, James W. Scholey, and Judith A. Miller* 1443

Endothelial-derived vasoactive mediators in polycystic kidney disease. *Muna A. Al-Nimri, Radko Komers, Terry T. Oyama, Arohan R. Subramanya, Jessie N. Lindsley, and Sharon Anderson* 1776

Effect of green tea extract on cardiac hypertrophy following 5/6 nephrectomy in the rat. *Snigdha Priyadarshi, Brandon Valentine, Chi Han, Olga V. Fedorova, Alexei Y. Bagrov, Jiang Liu, Sankaridrug M. Periyasamy, David Kennedy, Deepak Malhotra, Zijian Xie, and Joseph I. Shapiro* 1785

Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. *Eileen R. Blasi, Ricardo Rocha, Amy E. Rudolph, Eric A.G. Blomme, Melissa L. Polly, and Ellen G. McMahon* 1791

Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy. *Ulf Janssen, Stephen G. Riley, Athina Vassiliadou, Jürgen Floege, and Aled O. Phillips* 2162

Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: Comparison with apoprotein CIII. *Tsutomu Hirano, Taro Sakaue, Asako Misaki, Satoru Murayama, Toshihiro Takahashi, Kenta Okada, Hiroko Takeuchi, Gen Yoshino, and Mitsuru Adachi* 2171

Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat. *Johannes Bauer and Niranjan Parekh* 2178

Contents continued on next page

Contributions of nitric oxide, EDHF, and EETs to endothelium-dependent relaxation in renal afferent arterioles. *Dan Wang, Lillian J. Borrego-Conde, John R. Falck, Kamalesh K. Sharma, Christopher S. Wilcox, and Jason G. Umans* 2187

CLINICAL NEPHROLOGY – EPIDEMIOLOGY – CLINICAL TRIALS

Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. *Daniel W. Coyne, N. Franklin Adkinson, Jr., Allen R. Nissenson, Steven Fishbane, Rajiv Agarwal, Joseph W. Eschbach, Beckie Michael, Vaughn Folkert, Daniel Batlle, J. Richard Trout, Naomi Dahl, Pamela Myirski, Jur Strobos, and David G. Warnock, for the Ferlecit® Investigators* 217

Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). *Amanda I. Adler, Richard J. Stevens, Sue E. Manley, Rudy W. Bilous, Carole A. Cull, and Rury R. Holman, on behalf of the UKPDS Group* 225

Familial collapsing glomerulopathy: Clinical, pathological and immunogenetic features. *M. Carmen Avila-Casado, Gilberto Vargas-Alarcon, Maria E. Soto, Guadalupe Hernandez, Pedro A. Reyes, and Jaime Herrera-Acosta* 233

Long-term combined treatment with thiazide and potassium citrate in nephrolithiasis does not lead to hypokalemia or hypochloremic metabolic alkalosis. *Clarita V. Odvina, Glenn M. Preminger, Jill S. Lindberg, Orson W. Moe, and Charles Y.C. Pak* 240

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. *Jill S. Lindberg, Sharon M. Moe, William G. Goodman, Jack W. Coburn, Stuart M. Sprague, Wei Liu, Peter W. Blaisdell, Robert M. Brenner, Stewart A. Turner, and Kevin J. Martin* 248

Urine stone risk factors in nephrolithiasis patients with and without bowel disease. *Joan H. Parks, Elaine M. Worcester, R. Corey O'Connor, and Fredric L. Coe* 255

Severe bone disease and low bone mineral density after juvenile renal failure. *Jaap W. Groothoff, Martin Offringa, Berthe L.F. van Eck-Smit, Mariken P. Gruppen, Nicole J. van de Kar, Eric D. Wolff, Marc R. Lilien, Jean Claude Davin, Hugo S.A. Heymans, and Friedo W. Dekker* 266

Renal function and outcome of PTRA and stenting for atherosclerotic renal artery stenosis. *Felipe Ramos, Carol Kotliar, Daniel Alvarez, Hugo Baglivo, Pablo Rafaelle, Hugo Londero, Ramiro Sánchez, and Christopher S. Wilcox* 276

Impaired K^+ regulation contributes to exercise limitation in end-stage renal failure. *Termboon Sangkabutra, David P. Crankshaw, Claudia Schneider, Steve F. Fraser, Simon Sostaric, Kim Mason, Caroline M. Burge, Sandford L. Skinner, Lawrence P. McMahon, and Michael J. McKenna* 283

Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index. *Christopher W. Glanton, Tzu-Cheg Kao, David Cruess, Lawrence Y.C. Agodoa, and Kevin C. Abbott* 647

C-reactive protein is associated with renal function abnormalities in a non-diabetic population. *Erik M. Stuveling, Hans L. Hillege, Stephan J.L. Bakker, Reinold O.B. Gans, Paul E. de Jong, and Dick de Zeeuw* 654

Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. *John R. Asplin, Kimberly A. Bauer, Jennifer Kinder, Georg Müller, Brian J. Coe, Joan H. Parks, and Fredric L. Coe* 662

Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. *Marjan C. Slot, Jan Willem Cohen Tervaert, Casper F.M. Franssen, and Coen A. Stegeman* 670

Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. *Robert W. Schrier, Kimberly K. McFann, and Ann M. Johnson* 678

Apolipoprotein E in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. *Maurizio Bruschi, Paolo Catarsi, Giovanni Candiano, Maria Pia Rastaldi, Luca Musante, Francesco Scolari, Mary Artero, Michele Carraro, Alba Carrea, Gianluca Caridi, Cristina Zennaro, Simone Sanna-Cherchi, Fabio Battista Viola, Franco Ferrario, Francesco Perfumo, and Gian Marco Ghiggeri* 686

Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. *Holger Reinecke, Torsten Trey, Fritz Matzkies, Manfred Fobker, Günter Breithardt, and Roland M. Schaefer* 696

Dietary risk factors for hyperoxaluria in calcium oxalate stone formers. *Roswitha Siener, Dagmar Ebert, Claudia Nicolay, and Albrecht Hesse* 1037

Blood lead and chronic kidney disease in the general United States population: Results from NHANES III. *Paul Muntner, Jiang He, Suma Vupputuri, Josef Coresh, and Vecihi Batuman* 1044

High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. *Liam F. Casserly, Amit Fadia, Vaishali Sanchorawala, David C. Seldin, Daniel G. Wright, Martha Skinner, and Laura M. Dember* 1051

Cardiac disease in young adult patients with end-stage renal disease since childhood: A Dutch cohort study. *Mariken P. Gruppen, Jaap W. Groothoff, Martin Prins, Poll van der Wouw, Martin Offringa, Willem Jan Bos, Jean Claude Davin, and Hugo S.A. Heymans* 1058

Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients. *Alessandra Calábria Baxmann, Claudia De O.G. Mendonça, and Ita Pfeferman Heilberg* 1066

Gentamicin pharmacokinetics during slow daily home hemodialysis. *Harold J. Manley, George R. Bailie, Marcy L. McClaran, and Walter L. Bender* 1072

Serial ANCA titers: Useful tool for prevention of relapses in ANCA-associated vasculitis. *Won K. Han, Hyon K. Choi, Rachel M. Roth, Robert T. McCluskey, and John L. Niles* 1079

Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. *Yoshikatsu Kaneko, Shigeru Miyazaki, Yoshihei Hirasawa, Fumitake Gejyo, and Masashi Suzuki* 1086

Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. *Ruth Campbell, Fabio Sangalli, Elena Perticucci, Claudio Aros, Cecilia Viscarra, Annalisa Perna, Andrea Remuzzi, Federico Bertocchi, Luca Fagiani, Giuseppe Remuzzi, and Piero Ruggenenti* 1094

Role of endogenous nitric oxide in unilateral ureteropelvic junction obstruction in children. *Patricia G. Vallés, Luis Pascual, Walter Manucha, Liliana Carrizo, and Maria Rüttler* 1104

Total hip bone mass predicts survival in chronic hemodialysis patients. *Maarten W. Taal, Simon Roe, Tahir Masud, Desmond Green, Christine Porter, and Michael J.D. Cassidy* 1116

Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. *Guruprasad Manjunath, Hocine Tighiouart, Josef Coresh, Bonnie MacLeod, Deeb N. Salem, John L. Griffith, Andrew S. Levey, and Mark J. Sarnak* 1121

Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. *Jordan L. Rosenstock, Glen S. Markowitz, Anthony M. Valeri, Giuseppe Sacchi, Gerald B. Appel, and Vivette D. D'Agati* 1450

Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study. *Robert N. Foley, Charles A. Herzog, and Allan J. Collins* (see Editorial by Orth and Uehlinger, p. 1580) 1462

Proteinuria and the risk of developing end-stage renal disease. *Kunitoshi Iseki, Yoshiharu Ikemiya, Chiho Iseki, and Shuichi Takishita* 1468

The *FcγRIIIA-F158* allele is a risk factor for the development of lupus nephritis: A meta-analysis. *Fotini B. Karassa, Thomas A. Trikalinos, John P.A. Ioannidis, and FCγRIIIA-SLE meta-analysis investigators* 1475

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. *Stuart M. Sprague, Francisco Llach, Michael Amdahl, Carol Taccetta, and Daniel Batlle* 1483

Nutrition in hemodialysis patients previously on a supplemented very low protein diet. *Benoît Vendrely, Philippe Chauveau, Nicole Barthe, Wael El Haggan, Françoise Castaing, Valérie de Précigout, Christian Combe, and Michel Aparicio* 1491

Contents continued on next page

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. *William F. Keane, Barry M. Brenner, Dick de Zeeuw, Jean-Pierre Grunfeld, Janet McGill, William E. Mitch, Artur B. Ribeiro, Shahnaz Shaninfar, Roger L. Simpson, Steven M. Snapinn, and Robert Toto, for the RENAAL Study Investigators* 1499

Risk factors for renal glomerular and vascular changes in an autopsy-based population survey: The Hisayama Study. *Michiaki Kubo, Yutaka Kiyohara, Isao Kato, Yumihiro Tanizaki, Ritsuko Katafuchi, Hideki Hirakata, Seiya Okuda, Masazumi Tsuneyoshi, Katuo Sueishi, Masatoshi Fujishima, and Mitsuo Iida* 1508

Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. *Isidro B. Salusky, William G. Goodman, Beatriz D. Kuizon, Jeffrey R. Lavigne, Richard J. Zahranik, Barbara Gales, He-Jing Wang, Robert M. Elashoff, and Harald Jüppner* 1801

Histomorphometric features of bone in patients with primary and secondary hypoparathyroidism. *Yoshifumi Ubara, Tomohisa Fushimi, Tetsuo Tagami, Naoki Sawa, Junichi Hoshino, Masafumi Yokota, Hideyuki Katori, Fumi Takemoto, and Shigeko Hara* 1809

Time trends in reported prevalence of kidney stones in the United States: 1976–1994. *Kiriaki K. Stamatelou, Mildred E. Francis, Camille A. Jones, Leroy M. Nyberg, Jr., and Gary C. Curhan* (see Editorial by Goldfarb, p. 1951) 1817

Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease. *Mark M. Belz, Godela M. Fick-Brosnahan, Richard L. Hughes, David Rubinstein, Arlene B. Chapman, Ann M. Johnson, Kim K. McFann, William D. Kaehny, and Patricia A. Gabow* 1824

Association of transforming growth factor-beta (TGF-β) T869C (Leu 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese. *Teresa Yuk Hwa Wong, Peter Poon, Kai Ming Chow, Cheuk Chun Szeto, Man Kuen Cheung, and Philip Kam Tao Li* 1831

The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney disease. *Wolfgang C. Winkelmayer, Raisa Levin, and Jerry Avorn* 1836

The association between mental health, physical function, and hemodialysis mortality. *Eric L. Knight, Norma Ofsthun, Ming Teng, J. Michael Lazarus, and Gary C. Curhan* 1843

Aortic pulse wave velocity index and mortality in end-stage renal disease. *Jacques Blacher, Michel E. Safar, Alain P. Guerin, Bruno Pannier, Sylvain J. Marchais, and Gérard M. London* 1852

The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. *Yuansheng Xie, Shinichi Nishi, Mitsuhiro Ueno, Naofumi Imai, Minoru Sakatsume, Ichiei Narita, Yasushi Suzuki, Kouhei Akazawa, Hisaki Shimada, Masaaki Arakawa, and Fumitake Gejyo* 1861

Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. *Amit Fadia, Liam F. Casserly, Vaishali Sanchorawala, David C. Seldin, Daniel G. Wright, Martha Skinner, and Laura M. Dember* 1868

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. *Peter Jacobsen, Steen Andersen, Kasper Rossing, Berit R. Jensen, and Hans-Henrik Parving* 1874

Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants. *Przemyslaw Sikora, Bernhard Roth, Angela Kribs, Dietrich V. Michalk, Albrecht Hesse, and Bernd Hoppe* 2194

Cross-sectional and prospective data on urinary calcium and urinary stone disease. *Massimo Cirillo, Davide Stellato, Paolo Panarelli, Martino Laurenzi, and Natale G. De Santo, for the Gubbio Study Research Group* 2200

Peroxynitrite-induced oxidation of plasma lipids is enhanced in stable hemodialysis patients. *Barbara Ferraro, Francesco Galli, Balz Frei, Edward Kingdon, Franco Canestrari, Catherine Rice-Evans, Umberto Buoncristiani, Andrew Davenport, and Kevin P. Moore* 2207

Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis. *Carmela Iodice, Mario M. Balletta, Roberto Minutolo, Paolo Giannattasio, Stefano Tuccillo, Vincenzo Bellizzi, Maurizio D'Amora, Giorgio Rinaldi, Giuseppe Signoriello, Giuseppe Conte, and Luca De Nicola* 2214

Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. *Rachel A. Burdick, Jennifer L. Bragg-Gresham, John D. Woods, Sara A. Hedderwick, Kiyoshi Kurokawa, Christian Combe, Akira Saito, John Labrecque, Friedrich K. Port, and Eric W. Young* 2222

Microsatellite DNA polymorphism of human adrenomedullin gene in type 2 diabetic patients with renal failure. *Toshihiko Ishimitsu, Kohju Tsukada, Junichi Minami, Hidehiko Ono, Masami Ohrui, Jun Hino, Kenji Kangawa, and Hiroaki Matsuoka* 2230

Hepatitis C virus–related cryoglobulinemic glomerulonephritis: Long-term remission after antiviral therapy. *Paolo Rossi, Tullio Bertani, Piero Baio, Roberta Caldara, Patrizia Luliri, Francesca Tengattini, Piermario Bellavita, Gianna Mazzucco, and Rocco Misiani* 2236

A novel HIV-1 transgenic rat model of childhood HIV-1–associated nephropathy. *Patricio E. Ray, Xue-Hui Liu, Louis R. Robinson, William Reid, Lian Xu, Jennie W. Owens, Odell D. Jones, Frank Denaro, Harry G. Davis, and Joseph L. Bryant* 2242

Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. *Piero Ruggenenti, Annalisa Perna, and Giuseppe Remuzzi, on behalf of the Investigators of the Gisen Group* 2254

DIALYSIS–TRANSPLANTATION

Muscle atrophy in patients receiving hemodialysis: Effects on muscle strength, muscle quality, and physical function. *Kirsten L. Johansen, Tiffany Shubert, Julie Doyle, Brian Soher, Giorgos K. Sakkas, and Jane A. Kent-Braun* 291

Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? *Martin Zeier, Vedat Schwenger, Reinhold Deppisch, Ulrike Haug, Kai Weigel, U. Bahner, Christoph Wanner, H. Schneider, Thomas Henle, and Eberhard Ritz* 298

Inhibition of nuclear factor-κB activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy. *Satoshi Tamada, Tatsuya Nakatani, Toshihiro Asai, Koichiro Tashiro, Toshiyuki Komiya, Tomohiko Sumi, Mikio Okamura, Shokei Kim, Hiroshi Iwao, Taketoshi Kishimoto, Shinya Yamanaka, and Katsuyuki Miura* 306

Impact of albumin synthesis rate and the acute phase response in the dual regulation of fibrinogen levels in hemodialysis patients. *George A. Kaysen, Joel A. Dubin, Hans-Georg. Müller, William E. Mitch, Laura Rosales, Nathan W. Levin, and the HEMO Group* (see Editorial by Goodship, p. 314) 315

Creation, cannulation and survival of arteriovenous fistulae: Data from the Dialysis Outcomes and Practice Patterns Study. *Hugh C. Rayner, Ronald L. Pisoni, Brenda W. Gillespie, David A. Goodkin, Takashi Akiba, Tadao Akizawa, Akira Saito, Eric W. Young, and Friedrich K. Port* 323

Affinity adsorption of glucose degradation products improves the biocompatibility of conventional peritoneal dialysis fluid. *Naoyoshi Ishikawa, Toshio Miyata, Yasuhiko Ueda, Reiko Inagi, Yuko Izuhara, Hiroko Yuzawa, Hiroshi Onogi, Makoto Nishina, Masaomi Nangaku, Charles van Ypersele de Strihou, and Kiyoshi Kurokawa* 331

Prevention of *Staphylococcus aureus* biofilm on dialysis catheters and adherence to human cells. *Naomi Balaban, Yael Gov, Arkady Bitler, and Johan R. Boelaert* 340

Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients. *Christopher D. Miller, Michelle L. Robbin, and Michael Allon* 346

Effects of high-flux hemodialysis on oxidant stress. *Richard A. Ward, Rosemary Ouseph, and Kenneth R. McLeish* 353

Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. *G.V. Ramesh Prasad, Aasia Ahmed, Michelle M. Nash, and Jeffrey S. Zaltzman* 360

Contents continued on next page

Tissue adhesion to bioactive glass-coated silicone tubing in a rat model of peritoneal dialysis catheters and catheter tunnels. *Edward A. Ross, Christopher D. Batich, William L. Clapp, Judith E. Sallustio, and Nadeen C. Lee* 702

Effects of long and short hemodialysis on endothelial function: A short-term study. *David O. McGregor, Adrian L. Buttimore, Kelvin L. Lynn, Timothy Yandle, and M. Gary Nicholls* 709

Glomerulonephritis and malignancy: A population-based analysis. *Sven Arvid Birkeland and Hans H. Storm* 716

High glucose levels inhibit focal adhesion kinase-mediated wound healing of rat peritoneal mesothelial cells. *Masahito Tamura, Akihiko Osajima, Shingo Nakayamada, Hirofumi Anai, Narutoshi Kabashima, Kaori Kanegae, Takayuki Ota, Yoshiya Tanaka, and Yasuhide Nakashima* 722

Effects of uremic ultrafiltrate on the regulation of the parathyroid cell cycle by calcitriol. *Antonio Canalejo, Yolanda Almadén, Rita De Smet, Griet Glorieux, Bartolome Garfia, Fernando Luque, Raymond Vanholder, and Mariano Rodríguez* 732

Influenza vaccine delivery and effectiveness in end-stage renal disease. *David T. Gilbertson, Mark Unruh, A. Marshall McBean, Annamaria T. Kausz, Jon J. Snyder, and Allan J. Collins* 738

A prospective cohort study of incident maintenance dialysis in children: An NAPRTC study. *Mary B. Leonard, Lynn A. Donaldson, Martin Ho, and Denis F. Geary* 744

Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. *Martin Haas, Zdenka Leko-Mohr, Paul Roschger, Josef Kletzmayr, Christoph Schwarz, Christa Mitterbauer, Rudolf Steininger, Stefan Grampp, Klaus Klaushofer, Günter Delling, and Rainer Oberbauer* 1130

Nonheart-beating kidney donation: Current practice and future developments. *Nicholas R. Brook, Julian R. Waller, and Michael L. Nicholson* 1516

Myofibroblastic conversion of mesothelial cells. *An Hang Yang, Jinn Yang Chen, and Jen Kou Lin* 1530

Studies on dialysate mixing in the Genius® single-pass batch system for hemodialysis therapy. *Annemieke W. Dhondt, Raymond C. Vanholder, Rita V. De Smet, Stefaan A. Claus, Marie-Anne Waterloos, Griet L. Glorieus, Joris R. Delanghe, and Norbert H. Lameire* 1540

Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model. *Kazuhisa Minamiguchi, Keiko T. Kitazato, Hideki Nagase, Eeji Sasaki, Katsuo Ohwada, and Kenji Kitazato* 1548

Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study. *Constantijn J.A.M. Konings, Jeroen P. Kooman, Marc Schonck, Ulrich Gladziwa, Joris Wirtz, A. Warmold van den Wall Bake, Paul G. Gerlag, Steven J. Hoorntje, Johannes Wolters, Frank M. van der Sande, and Karel M.L. Leunissen* 1556

Heme oxygenase-1 attenuates ischemia/reperfusion-induced apoptosis and improves survival in rat renal allografts. *Markus Wagner, Petra Cadetg, Rainer Ruf, Luca Mazzucchelli, Paolo Ferrari, and Claudio A. Redaelli* 1564

Vitamin E–bonded hemodialyzer improves atherosclerosis associated with a rheological improvement of circulating red blood cells. *Shuzo Kobayashi, Hidekazu Moriya, Kuniko Aso, and Takayasu Ohtake* . . . 1881

Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. *Alex B. Magil and Kathryn Tinckam* (see Editorial by Colvin, p. 1953) 1888

Slow-flow venous pressure for detection of arteriovenous graft malfunction. *Gary R. Sirken, Chetan Shah, and Rasib Raja* 1894

Cardiac hypertrophy and remodeling in relation to ACE and angiotensinogen genes genotypes in Chinese dialysis patients. *Angela Yee-Moon Wang, Juliana Chung-Ngor Chan, Mei Wang, Emily Poon, Siu-Fai Lui, Philip Kam-Tao Li, and John Sanderson* 1899

The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. *Norma Ofsthun, John LaBrecque, Eduardo Lacson, Marcia Keen, and J. Michael Lazarus* 1908

The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. *Eudocia Rojas, Raul G. Carlini, Paul Clesca, Anabella Arminio, Orlando Suniaga, Karen de Elguezabal, José R. Weisinger, Keith A. Hruska, and Ezequiel Bellorin-Font* 1915

Elevation of blood thioredoxin in hemodialysis patients with hepatitis C virus infection. *Akihiko Kato, Mari Odamaki, Hajime Nakamura, Junji Yodoi, and Akira Hishida* 2262

Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. *Eddy Hernández, Raquel Valera, Evelyn Alonzo, Mariela Bajares-Lilue, Raúl Carlini, Freya Capriles, Ruby Martinis, Ezequiel Bellorin-Font, and José R. Weisinger* 2269

Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. *Stanley L-S. Fan, Serita Kumar, and John Cunningham* 2275

Effects of the glutamate carboxypeptidase II (*GCP2* 1561C>T) and reduced folate carrier (*RFC1* 80G>A) allelic variants on folate and total homocysteine levels in kidney transplant patients. *Wolfgang C. Winkelmayer, Corinna Eberle, Gere Sunder-Plassmann, and Manuela Födinger* 2280

Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. *Koichi Suzuki, Kazuho Honda, Kazunari Tanabe, Hiroshi Toma, Hiroshi Nihei, and Yutaka Yamaguchi* 2286

The clinical characteristics and antiretroviral dosing patterns of HIV-infected patients receiving dialysis. *Lynda Anne Szczech, Robert Kalayjian, Rudolph Rodriguez, Samir Gupta, Joseph Coladonato, and Jonathan Winston, for the Adult Aids Clinical Trial Group Renal Complications Committee* 2295

Hypertension increases expression of growth factors and MHC II in chronic allograft nephropathy. *Ralf Schindler, Stefan G. Tullius, Yakup Tanriver, Kerstin Noack, Ye Qun, Jan-Steffen Jürgensen, and Ulrich Frei* 2302

Health-related fitness and quality of life following steroid withdrawal in renal transplant recipients. *Patricia L. Painter, K.S. Topp, J.B. Krasnoff, D. Adey, A. Strasner, S. Tomlanovich, and P. Stock* 2309

TECHNICAL NOTE

Morphogenesis during mouse embryonic kidney explant culture. *Indra Rani Gupta, Martine Lapointe, and Oriana H. Yu* 365

Effects of carboxy-terminal modifications of proteinase 3 (PR3) on the recognition by PR3-ANCA. *Stephen A. Capizzi, Margaret A. Viss, Amber M. Hummel, David N. Fass, and Ulrich Specks* 756

Free cysteine is increased in plasma from hemodialysis patients. *Takeshi Nakanishi, Yukiko Hasuike, Yoshinaga Otaki, Yasue Hama, Masayoshi Nanami, Koji Miyagawa, Rintaro Moriguchi, Hirofumi Nishikage, Masaaki Izumi, and Yoshihiro Takamitsu* 1137

An in vivo method for adenovirus-mediated transduction of thick ascending limbs. *Pablo A. Ortiz, Nancy J. Hong, Craig F. Plato, Marisela Varela, and Jeffrey L. Garvin* 1141

Effect of a novel adsorbent on cytokine responsiveness to uremic plasma. *Marion D. Morena, Daqing Guo, Vaidyanathapuram S. Balakrishnan, James A. Brady, James F. Winchester, and Bertrand L. Jaber* 1150

Prevention of biofilm formation in dialysis water treatment systems. *Ed Smeets, Jeroen Kooman, Frank van der Sande, Ellen Stobberingh, Peter Frederik, Piet Claessens, Willem Grave, Arend Schot, and Karel Leunissen* 1574

Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. *Borislav D. Dimitrov, Annalisa Perna, Piero Ruggenenti, and Giuseppe Remuzzi* 1924

Review on uremic toxins: Classification, concentration, and interindividual variability. *Raymond Vanholder, Rita De Smet, Griet Glorieux, Angel Argilés, Ulrich Baurmeister, Philippe Brunet, William Clark, Gerald Cohen, Peter Paul De Deyn, Reinhold Deppisch, Beatrice Descamps-Latscha, Thomas Henle, Achim Jörres, Horst Dieter Lemke, Ziad A. Massy, Jutta Passlick-Deetjen, Mariano Rodriguez, Bernd Stegmayr, Peter Stenvinkel, Ciro Tetta, Christoph Wanner, and Walter Zidek, For the European Uremic Toxin Work Group (EUTox)* 1934

Contents continued on next page

Impact of thyroid dysfunction on serum cystatin C. *Manuel Fricker, Peter Wiesli, Michael Brändle, Beat Schwegler, and Christoph Schmid* 1944

COMMENTARY

Muscle crush compartment syndrome: Fulminant local edema with threatening systemic effects. *Ori S. Better, Irit Rubinstein, and Daniel N. Reis* 1155

Dialysis delayed is death prevented: A clinical perspective on the RENAAL study. *Merlin C. Thomas, Mark E. Cooper, Shahnaz Shahinfar, and Barry M. Brenner* 1577

Preventing end-stage renal disease: The potential impact of screening and intervention in developing countries. *Arrigo Schieppati, Norberto Perico, and Giuseppe Remuzzi* 1948

EDITORIALS

Immunosuppression for diabetic glomerular disease? *Timothy W. Meyer* 377

Fibrinogen in hemodialysis: The worst of both worlds? *Timothy H.J. Goodship* 379

Congential obstructive nephropathy gets complicated. *Adrian S. Woolf* 761

Renoprotection: Clues from knockout models of rare diseases. *Mauro Abbate and Giuseppe Remuzzi* .. 764

Of laminins and delamination in Alport syndrome. *Jeffrey H. Miner* 1158

A refined understanding of immunosuppressives and cancer risk. *Vikas P. Sukhatme and Terry B. Strom* .. 1160

Hyaline arteriolosclerosis: New meaning for an old lesion. *Jean L. Olson* 1162

Smoking and dialysis: A dreadful scenario for the cardiovascular system? *Stephen R. Orth and Dominik E. Uehlinger* 1580

A role for macrophages in mediating tubular cell apoptosis? *David J. Nikolic-Paterson* 1582

Interactions between growth factors in the kidney: Implications for progressive renal injury. *Mark Cooper and Merlin C. Thomas* 1584

Increasing prevalence of kidney stones in the United States. *David S. Goldfarb* 1951

Transplant Mac attack: Humor the macrophages. *Robert B. Colvin* 1953

A new partnership between TGF-β1 and glucocorticoids in the network of inflammation. *Oliver M. Steinmetz and Rolf A.K. Stahl* 2317

LETTERS TO THE EDITOR

Tumor-suppressive effect of connexin 32 in renal cell carcinoma from maintenance hemodialysis patients. *Tomohiro Yano, Fumio Ito, Haruna Satoh, Kiyokau Hagiwara, Hayakazu Nakazawa, Hiroshi Toma, and Hiroshi Yamasaki* 381

Calcium on trial: Beyond a reasonable doubt? *Caterina Canavese, Daniela Bergamo, Hamido Dib, Francesca Bermond, and Manuel Burdese* 381

Albert Fournier, Mohamed Benyahia, Crina Popa Claudia, and Tarek Sadek 382

Mark Cleveland 383

Charles R. Nolan and Wajah Y. Quinibi 383

Nuclear factors, hs1,2 enhancer and IgA nephropathy. *Barbara Bessette, Laurence Guglielmi, Michel Cogné, and Yves Denizot* 767

Venous central catheter and risk of death among hemodialysis patients. *Biagio Raffaele Di Iorio and Carmela Iodice* 767

Dual blockade of renin-angiotensin system. *Atsuo Goto* 768

The antiproteinuric effect of high-dose ramipril: Still an open question. *Antonio Piccoli and Luana Pillon* .. 769

The statement that folate supraphysiological levels in uremic patients do not cause harm should not go unchallenged. *Caterina Canavese, Daniela Bergamo, Giulio Mengozzi, Giuseppe Aimo, Luisa Sandri, and Antonio Marciello* 771

Update on vitamin D and its newer analogues. *Albert Fournier, Abderhamane Ghazali, Claire Presne, and Michele Garabedian* 1586

Concerns about KIM-1 as a urinary biomarker for acute tubular necrosis (ATN). *Seymour Rosen and Samuel Heyman* 1955

Calciphylaxis is usually nonulcerating: Risk factors, outcomes, and therapy. *Prem K.G. Chandran* 1955

A comparison of transplant outcomes in peritoneal and hemodialysis patients. *Miguel Pérez Fontán and Ana Rodríguez-Carmona* 1956

Overnight unattended home hemodialysis. *Stanley Shaldon* 1957

Influence of dialysis membranes on outcomes in acute renal failure. *Marcello Tonelli, Neesh Pannu, and Braden Manns* 1957

Posttransplant hemolytic uremic syndrome. *Colm C. Magee, Mark D. Denton, and Manuel Pascual* 1958

Thrombotic microangiopathy following organ transplantation. *Phuong-Thu T. Pham, Phuong-Chi T. Pham, and Alan H. Wilkinson* 1959

Endothelial chimerism in association with vascular rejection in patients after kidney transplantation. *Shigeru Horita, Kosaku Nitta, Kazunari Tanabe, Hiroshi Nihei, Hiroshi Toma, and Yutaka Yamaguchi* . 1960

Risk factors for late kidney allograft failure. *Navalkishor Udgiri, Randeep Kashyap, and Mukut Minz* . . 1960

Bitter pill it is, but frequent hemodialysis more than thrice weekly may be the answer. *Abdulla K. Salahudeen and Warren May* 1961

Infection rates of the LifeSite hemodialysis access system. *John J. Ross, Geetha Narayan, Michael G. Worthington, and James A. Strom* 1963

NEPHROLOGY FORUM

Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy. *Charles E. Alpers* 385

Tubular injury in glomerular disease. *Timothy W. Meyer* 774

Rapidly progressive crescentic glomerulonephritis. *J. Charles Jennette* 1164

Adequacy of dialysis revisited. *Peter G. Blake* 1587

Molecular mechanisms of lipid disorders in nephrotic syndrome. *Nosratola D. Vaziri* 1964

Clinical and cellular markers of diabetic nephropathy. *Daniel Batlle* 2319

INTERNATIONAL SOCIETY OF NEPHROLOGY

ISN Council 2003–2009 Elections 1178

International Society of Nephrology 2001 Awards 2331

Meetings 398, 788, 1183, 1600, 1977, 2342

Books Received 790, 1602, 2345

Awards and Grants 791, 1185, 1602, 1979, 2343

Errata 400, 1602, 2345

ACKNOWLEDGMENT OF CORPORATE SPONSORS 2347

ACKNOWLEDGMENT OF REVIEWERS 2348

AUTHOR INDEX 2353

VOLUME 63 ACCUMULATED TABLE OF CONTENTS 2378

KIDNEY INTERNATIONAL

Volume 63, Supplement 83, February 2003

Renal Disease in Racial and Ethnic Minority Groups

A Satellite Meeting of the World Congress of Nephrology

Santa Fe, New Mexico

October 19–20, 2001

Table of contents

Introduction. *David J. Pugsley, Lawrence Agodoa, and Robert G. Nelson* S-1

PATHOPHYSIOLOGY AND ETIOLOGY OF CHRONIC RENAL DISEASE

The spectrum of kidney disease in American Indians. *Andrew S. Narva* S-3

Genetics of kidney disease. *Donald W. Bowden* S-8

Intrauterine determinants of diabetic kidney disease in disadvantaged populations. *Robert G. Nelson* .. S-13

Hypertensive risk factors in kidney disease in African Americans. *Agnes B. Fogo* S-17

End-stage renal disease and acute glomerulonephritis in Goajiro Indians. *José Herrera and Bernardo Rodríguez-Iturbe* S-22

Insulin resistance in African Americans. *Bonita Falkner* S-27

A stereological study of glomerular number and volume: Preliminary findings in a multiracial study of kidneys at autopsy. *Wendy E. Hoy, Rebecca N. Douglas-Denton, Michael D. Hughson, Alan Cass, Kelli Johnson, and John F. Bertram* S-31

A basis for accelerated progression of diabetic nephropathy in Pima Indians. *Kevin V. Lemley* S-38

HIV-associated nephropathy in African Americans. *Jeffrey B. Kopp and Cheryl Winkler* S-43

PREVENTION AND TREATMENT OF RENAL DISEASE

Identification of persons at high risk for kidney disease via targeted screening: The NKF Kidney Early Evaluation Program. *Wendy W. Brown, Allan Collins, Shu-Cheng Chen, Karren King, Donald Molony, Monica R. Gannon, Gigi Politoski, and William F. Keane* S-50

A nephrological program in Benin and Togo (West Africa). *Giovanni B. Fogazzi, Vénérand Attolou, Solomon Kadiri, Domenico Fenili, and Fiorenzo Priuli* S-56

Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program. *Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, and William McClellan* S-61

Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. *Wendy E. Hoy, Zhiqiang Wang, Philip R.A. Baker, and Angela M. Kelly* S-66

ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: The African American Study of Kidney Disease and Hypertension (AASK) trial. *Janice G. Douglas and Lawrence Agodoa* ... S-74

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors. *Barry M. Brenner and JoAnn Zagrobelny* S-77

Prevention of chronic renal failure at the community level. *Muthu K. Mani* S-86

Peritoneal dialysis in Mexico. *Alfonso M. Cueto-Manzano* S-90

Hemodialysis: Management problems in developing countries, with Nigeria as a surrogate. *Ebun L. Bamgboye* S-93

Renal transplantation in developing countries. *S. Adibul Hansan Rizvi, S.A. Anwar Naqvi, Zafar Hussain, Altaf Hashmi, Fazal Akhtar, Manzoor Hussain, Ejaz Ahmed, M. Naqi Zafar, Saleem Hafiz, Rana Muzaffar, and Fatema Jawad* S-96

Paradigms of public-private partnerships in end-stage renal disease care: The National Kidney Foundation Singapore. *Sylvia Paz B. Ramirez, T.T. Durai, and Stephen I-Hong Hsu* S-101

END-STAGE RENAL DISEASE IN SELECTED GROUPS

Nephrology in China: A great mission and momentous challenge. *Shanyan Lin* S-108

End-stage renal disease in North Africa. *Rashad S. Barsoum* S-111

End-stage renal disease in India and Pakistan: Burden of disease and management issues. *Vinay Sakhuja and Kamal Sud* S-115

End-stage renal disease in sub-Saharan and South Africa. *Saraladevi Naicker* S-119

Burden of end-stage renal disease among indigenous peoples in Australia and New Zealand. *Stephen P. McDonald and Graeme R. Russ* S-123

Nephrology in South East Asia: Fact and concept. *Visith Sitprija* S-128

Nephrology in Latin America, with special emphasis on Brazil. *Roberto Zatz, J.E. Romão, Jr., and I.L. Noronha* S-131

Preventing renal disease: The ethnic challenge in the United Kingdom. *Liz Lightstone* S-135

Volume 63, Supplement 84, May 2003

Mechanism of Uremic Toxicity

and Cardiovascular Disease

Table of contents

Introduction. *Thomas Quaschning and Christoph Wanner* S-1

UREMIC TOXICITY

The uremic syndrome: Therapeutic-evaluative discordance. *Salim Mujais and Lee Henderson* S-2

New insights in uremic toxins. *R. Vanholder, G. Glorieux, R. De Smet, N. Lameire, for the European Uremic Toxin Work Group (EUTox)* S-6

Are advanced oxidation protein products potential uremic toxins?. *Véronique Witko-Sarsat, Valérie Gausson, and Béatrice Descamps-Latscha* S-11

Immunoglobulin light chains in uremia. *Gerald Cohen* S-15

N-methyl-2-pyridone-5-carboxamide: A novel uremic toxin? *Boleslaw Rutkowski, Ewa Slominska, Marek Szolkiewicz, Ryszard T. Smolenski, Cindy Striley, Przemyslaw Rutkowski, and Julian Swierczynski* S-19

OXIDATIVE STRESS AND NO

Nitric oxide, oxidative stress, and apoptosis. *Bernhard Brüne, Jie Zhou, and Andreas von Knethen* S-22

Nitric oxide in uremia: Effects of several potentially toxic guanidino compounds. *P.P. De Deyn, R. Vanholder, and R. D'Hooge* S-25

Oxidative consumption of nitric oxide: A potential mediator of uremic vascular disease. *R.C. Thuraisingham and M.M. Yaqoob* S-29

5-Lipoxygenase-mediated mitochondrial damage and apoptosis of mononuclear cells in ESRD patients. *Mauro Maccarrone, Massimo Taccone-Gallucci, and Alessandro Finazzi-Agrò* S-33

Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? *Danilo Fliser, Jan T. Kielstein, Hermann Haller, and Stefanie M. Bode-Böger* S-37

ENDOTHELIAL DYSFUNCTION

Endothelial permeability in uremia. *Steven J. Harper and David O. Bates* S-41

Endothelial dysfunction and inflammation: What is the link? *Jan Galle, Thomas Quaschning, Stefan Seibold, and Christoph Wanner* S-45

Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: Impact on cardiovascular disease. *Margus Annuk, Mihkel Zilmer, and Bengt Fellström* S-50

Vasopeptidase inhibition: A new treatment approach for endothelial dysfunction. *Thomas Quaschning, Jan Galle, and Christoph Wanner* S-54

INFLAMMATION, CYTOKINES, AND THE IMMUNE SYSTEM

Update on C-reactive protein as a risk marker in cardiovascular disease. *Wolfgang Koenig* S-58

Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients. *Marta Kalousová, Tomáš Zima, Vladimír Tesař, Sylvie Sulková, and Lenka Fialová* S-62

Adipose tissue as a source of inflammatory cytokines in health and disease: Focus on end-stage renal disease. *Carmine Zoccali, Francesca Mallamaci, and Giovanni Tripepi* S-65

Do circulating cytokines really matter in sepsis? *Ciro Tetta, Rinaldo Bellomo, Vincent D'Intini, Concetta De Nitti, Paola Inguaggiato, Alessandra Brendolan, and Claudio Ronco* S-69

The effect of viable *Chlamydia pneumoniae* on serum cytokines and adhesion molecules in hemodialysis patients. *George Tsirpanlis, Stylianos Chatzipanagiotou, Anastasios Ioannidis, Kostantina Ifanti, Pantelis Bagos, Antonis Lagouranis, Cornelia Poulopoulou, and Chrysoula Nicolaou* S-72

Uremia-associated immune defect: The IL-10–CRP axis. *Matthias Girndt, Christof Ulrich, Harald Kaul, Urban Sester, Martina Sester, and Hans Köhler* S-76

METABOLISM AND INFLAMMATION

Morphology of the heart and arteries in renal failure. *Karin Tyralla and Kerstin Amann* S-80

Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia. *Markus Ketteler, Christoph Wanner, Thomas Metzger, Philipp Bongartz, Ralf Westenfeld, Ulrich Gladziwa, Leon J. Schurgers, Cees Vermeer, Willi Jahnen-Dechent, and Jürgen Floege* S-84

Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. *Gérard M. London, Sylvain J. Marchais, Alain P. Guerin, Fabien Metivier, Hassan Adda, and Bruno Pannier* S-88

Factors that affect albumin concentration in dialysis patients and their relationship to vascular disease. *George A. Kaysen and Burl R. Don* S-94

Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. *Carmine Zoccali, Francesca Mallamaci, Vincenzo Panuccio, Giovanni Tripepi, Sebastiano Cutrupi, Saverio Parlongo, Francesco Catalano, Sachiyo Tanaka, Noriyuki Ouchi, Shinji Kihara, Tohru Funahashi, and Yuji Matsuzawa* S-98

Protein uptake disturbs collagen homeostasis in proximal tubule-derived cells. *Verena Wohlfarth, Karina Drumm, Sigrid Mildenberger, Ruth Freudinger, and Michael Gekle* S-103

DYSLIPIDEMIAS

Dialysis modalities and dyslipidemia. *Per-Ola Attman, Ola Samuelsson, Ann-Cathrine Johansson, James B. Moberly, and Petar Alaupovic* S-110

Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. *Florian Kronenberg, Arno Lingenhel, Ulrich Neyer, Karl Lhotta, Paul König, Martin Auinger, Martin Wiesholzer, Helene Andersson, and Hans Dieplinger* S-113

Non–high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. *Yoshiki Nishizawa, Tetsuo Shoji, Ryusuke Kakiya, Yoshihiro Tsujimoto, Tsutomu Tabata, Eiji Ishimura, Tatsuya Nakatani, Takami Miki, and Masaaki Inaba* S-117

Hypertriglyceridemia in patients with chronic renal failure: Possible mechanisms. *Berthil H.C.M.T. Prinsen, Monique G.M. de Sain-van der Velden, Eelco J.P. de Koning, Hein A. Koomans, Ruud Berger, and Ton J. Rabelink* S-121

New insights into the effects of the protein moiety of oxidized LDL (oxLDL). *Stéphanie Vicca, Ziad A. Massy, Carole Hennequin, Djamel Rihane, Thao Nguyen-Khoa, Tilman B. Drüeke, and Bernard Lacour* S-125

The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients. *Tetsuo Shoji, Eiji Kimoto, Kayo Shinohara, Masanori Emoto, Eiji Ishimura, Takami Miki, Yoshihiro Tsujimoto, Tsutomu Tabata, and Yoshiki Nishizawa* S-128

HOMOCYSTEINE

Homocysteine, renal function, and risk of cardiovascular disease. *Robert Clarke, Sarah Lewington, and Martin Landray* S-131

Potential strategies to normalize the levels of homocysteine in chronic renal failure patients. *Ziad A. Massy* S-134

Possible mechanisms of homocysteine toxicity. *Alessandra F. Perna, Diego Ingrosso, Cinzia Lombardi, Filomena Acanfora, Ersilia Satta, Concetta Maria Cesare, Eleonora Violetti, Maria Maddalena Romano, and Natale G. De Santo* S-137

Genetic determinants of the homocysteine level. *Gere Sunder-Plassmann and Manuela Födinger* S-141

CARBONYL STRESS AND AGES

AGEs in foods: Do they play a role in uremia? *Thomas Henle* S-145

Glucose degradation products in peritoneal dialysis fluids: Do they harm? *Janusz Witowski, Achim Jörres, with the assistance of Katarzyna Korybalska, Krzysztof Ksiazek, Justyna Wisniewska-Elnur, Thorsten O. Bender, Jutta Passlick-Deetjen, and Andrzej Breborowicz* S-148

Immunohistochemical detection of an AGE, a ligand for macrophage receptor, in peritoneum of CAPD patients. *Sakurako Nakamura, Kazuki Tobita, Tetsuya Tachikawa, Suguru Akamatsu, Yoshifumi Ohno, Ayumi Kan, Misaki Katsuragawa, Koichi Yasumura, Shigeru Miyazaki, Shinji Sakai, Takashi Morita, Yoshihei Hirashawa, and Toshimitsu Niwa* S-152

Peritoneal dialysis: Changes to the structure of the peritoneal membrane and potential for biocompatible solutions. *John D. Williams, Kathrine J. Craig, Nicholas Topley, and Geraint T. Williams* S-158

UREMIA, GENES, AND THE HEART

Genetic approaches in the clinical investigation of complex disorders: Malnutrition, inflammation, and atherosclerosis (MIA) as a prototype. *Roberto Pecoits-Filho, Louise Nordfors, Bengt Lindholm, Catherine M. Hoff, Martin Schalling, and Peter Stenvinkel* S-162

Cardiovascular pharmacogenetics: On the way toward individually tailored drug therapy. *Winfried Siffert* S-168

A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. *Roberto Pecoits-Filho, Peter Stenvinkel, Alicia Marchlewska, Olof Heimburger, Peter Bárány, Catherine M. Hoff, Clifford J. Holmes, Mohamed Suliman, Bengt Lindholm, Martin Schalling, and Louise Nordfors* S-172

Calpain is a mediator of myocardial injury in experimental uremia: Is it activated by endogenous ouabain? *Steven M. Harwood, David A. Allen, Martin J. Raftery, and Muhammad M. Yaqoob* S-177

Fabry disease: Diagnosis and treatment. *Frank Breunig, Frank Weidemann, Meinrad Beer, Andreas Eggert, Vera Krane, Matthias Spindler, Jörn Sandstede, Jörg Strotmann, and Christoph Wanner* S-181

Genetic aspects of diabetic nephropathy. *Tom H. Lindner, Detlev Mönks, Christoph Wanner, and Mario Berger* S-186

EPIDEMIOLOGY AND CLINICAL TRIALS

Cardiovascular risk in patients with mild renal insufficiency. *Johannes F.E. Mann, Hertzel C. Gerstein, Ioana Dulau-Florea, and Eva Lonn* S-192

Cardiac arrest in dialysis patients: Approaches to alter an abysmal outcome. *Charles A. Herzog* S-197

Cardiovascular risk factors in predialysis patients: Baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. *David C. Wheeler, John N. Townend, and Martin J. Landray* S-201

Why do we need a statin trial in hemodialysis patients? *Bengt C. Fellström, Hallvard Holdaas, and Alan G. Jardine* S-204

Study of Heart and Renal Protection (SHARP). *Colin Baigent and Martin Landry* S-207

Volume 63, Supplement 85, June 2003

Advances in Renal Osteodystrophy—

IV International Symposium

Table of contents

Advances in Renal Osteodystrophy—IV International Symposium. *Jorge B. Cannata-Andía, José L. Fernández-Martín, and Iñigo Santamaría* S-1

Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. *Brendan F. Boyce, Lianping Xing, William Shakespeare, Yihan Wang, David Dalgarno, John Iuliucci, and Tomi Sawyer* S-2

Vitamin D receptor: Mechanisms for vitamin D resistance in renal failure. *Adriana S. Dusso* S-6

Importance of arachidonic acid as a mediator of parathyroid gland response. *Antonio Canalejo, Sagrario Cañadillas, Evaristo Ballesteros, Mariano Rodriguez, and Yolanda Almaden* S-10

Influence of polymorphisms in VDR and COLIA1 genes on the risk of osteoporotic fractures in aged men. *Daniel Álvarez-Hernández, Manuel Naves, J. Bernardino Díaz-López, Carlos Gómez, Iñigo Santamaría, and Jorge B. Cannata-Andía* S-14

Response of parathyroid glands to calcitriol in culture: Is this response mediated by the genetic polymorphisms in vitamin D receptor? *Daniel Álvarez-Hernández, Manuel Naves, Íñigo Santamaría, Javier Menárguez, Vicente Torregrosa, and Jorge Cannata* S-19

Effect of VDR gene polymorphisms on osteocalcin secretion in calcitriol-stimulated human osteoblasts. *Manuel Naves, Daniel Álvarez-Hernández, José L. Fernández-Martín, José Paz-Jiménez, Pedro García-Prado, Teresa Fernández-Coto, Iñigo Santamaría, and Jorge Cannata-Andía* S-23

Comparative study of the expression of proteins involved in the cell cycle in renal secondary hyperparathyroidism. *José A. Alcázar, José R. Polo, Juan C. Tardío, Javier Anguita, Juan C. Martínez-Montero, Rosa Jofré, Francisco J. García-Criado, and Javier Menárguez* S-28

Chromosomal aberrations, the consequence of refractory hyperparathyroidism: Its relationship with biochemical parameters. *Sandra Afonso, Íñigo Santamaría, Martín E. Guinsburg, Ana Otero Gómez, José Luis García Miranda, Rosa Jofré, Javier Menárguez, Jorge Cannata-Andía, and Juan C. Cigudosa* S-32

Effect of aluminium on calcium-sensing receptor expression, proliferation, and apoptosis of parathyroid glands from rats with chronic renal failure. *Ignacio González-Suárez, Manuel Naves, Carmen Díaz-Corte, José L. Fernández-Martín, Primitiva Menéndez-Rodríguez, and Jorge B. Cannata-Andía* S-39

Vitamin D status and secondary hyperparathyroidism: The importance of 25-hydroxyvitamin D cut-off levels. *Carlos Gómez-Alonso, Manuel L. Naves-Díaz, Jose L. Fernández-Martin, Jose B. Díaz-López, Maria T. Fernández-Coto, and Jorge B. Cannata-Andía* S-44

Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4. *Jack W. Coburn and Hla M. Maung* S-49

The renal osteodystrophy pattern in Brazil and Uruguay: An overview. *Sonia M. Holanda Almeida Araújo, Pablo Ambrosoni, Rosélia R. Santos Lobão, Hena Caorsi, Rosa M.A. Moysés, Fellype Carvalho Barreto, Inés Olaizola, Elisa A.S. Cruz, Alicia Petraglia, Luciene M. Dos Reis, Maria Eugênia Duarte, Vanda Jorgetti, and Aluizio B. Carvalho* S-54

Hormonal replacement therapy in an animal model with chronic renal failure and ovariectomy: Biochemical and densitometric study. *A. Rodríguez-Rodríguez, M. Naves, A. Rodríguez-Rebollar, C. Gómez, S. Braga, and J.B. Cannata-Andía* S-57

Selective estrogen receptor modulators in chronic renal failure. *José R. Weisinger, Ita Pfeferman Heilberg, Eddy Hernández, Raul Carlini, and Ezequiel Bellorin-Font* S-62

Evolution of serum phosphate in long intermittent hemodialysis. *Laura Fajardo, Nieves Campistrús, Pablo Ríos, and Teresa Gómez* S-66

Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison with calcium acetate. *José G. Hervás, Dolores Prados, and Sebastián Cerezo* S-69

A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients. *Patrick C. D'Haese, Goce B. Spasovski, Aleksander Sikole, Alastair Hutchison, Tony J. Freemont, Sylvie Sulkova, Charles Swanepoel, Svetlana Pejanovic, Llubica Djukanovic, Alessandro Balducci, Giorgio Coen, Waldysaw Sulowicz, Anibal Ferreira, Armando Torres, Slobodan Curic, Milan Popovic, Nada Dimkovic, and Marc E. De Broe* S-73

Advantages of adjusting the initial dose of intravenous calcitriol according to PTH levels. *Minerva Rodríguez-García, José Luis Fernández-Martín, Jaime Ruiz de Castañeda, José Hervás-Sánchez, Jorge Benito Cannata-Andía, and the Caldial Study Group* S-79

New vitamin D analogs. *Eduardo Slatopolsky, Jane Finch, and Alex Brown* S-83

Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. *Jose-Vicente Torregrosa, Agustin Moreno, Merçe Mas, Joan Ybarra, and David Fuster* S-88

Calcimimetic agents: Review and perspectives. *Pablo Ureña and João M. Frazão* S-91

Parathyroidectomy: Whom and when? *Rosa Jofré, Juan Manuel López Gómez, Javier Menárguez, José Ramón Polo, Martin Guinsburg, Teresa Villaverde, Isabel Pérez Flores, Diana Carretero, Patrocinio Rodríguez Benitez, and Rafael Pérez García* S-97

Treatment of refractory secondary hyperparathyroidism with ethanol injection: The importance of glandular volume. *Walter G. Douthat, Santiago E. Orozco, Javier de Arteaga, and Pablo U. Massari* S-101

Traditional and emerging cardiovascular risk factors in end-stage renal disease. *Carmine Zoccali, Francesca Mallamaci, and Giovanni Tripepi* S-105

Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. *Maria Paz Marco, Lourdes Craver, Angels Betriu, Montserrat Belart, Joan Fibla, and Elvira Fernández* S-111

Heart valve calcification and calcium x phosphorus product in hemodialysis patients: Analysis of optimum values for its prevention. *Margarita Rufino, Sagrario García, Alejandro Jiménez, Alejandra Alvarez, Rosa Miquel, Patricia Delgado, Domingo Marrero, Armando Torres, Daniel Hernández, and Victor Lorenzo* S-115

Vascular calcification in the uremic patient: A cardiovascular risk? *Mercedes Salgueira, Nuria del Toro, Rafael Moreno-Alba, Elena Jiménez, Nuria Aresté, and Alfonso Palma* S-119

The evolving clinical features of calciphylaxis. *Francisco Llach* S-122

Bone remodeling after renal transplantation. *Ezequiel Bellorin-Font, Eudocia Rojas, Raul G. Carlini, Orlando Suniaga, and José R. Weisinger* S-125

Bone disease in long-term adult kidney transplant patients with normal renal function. *Coral Montalban, Angel L.M. de Francisco, Maria L. Mariñoso, Jose Antonio Zubimendi, Mayte García Unzueta, Jose A. Amado, and Manuel Arias* S-129